These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22302098)

  • 21. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
    Zhou Y; Liu H; Xue R; Tang W; Zhang S
    Dig Dis Sci; 2018 Dec; 63(12):3367-3375. PubMed ID: 30155839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
    Lee EY; Gong EY; Shin JS; Moon JH; Shim HJ; Kim SM; Lee S; Jeong J; Gong JH; Kim MJ; Lee DH; Park YS; Shin J; Hong SW; Kim YS; Jin DH
    Toxicol In Vitro; 2018 Feb; 46():229-236. PubMed ID: 28947240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
    Kutuk O; Letai A
    Cancer Res; 2008 Oct; 68(19):7985-94. PubMed ID: 18829556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
    Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
    Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
    J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
    Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
    Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
    Larson N; Yang J; Ray A; Cheney DL; Ghandehari H; Kopeček J
    Int J Pharm; 2013 Sep; 454(1):435-43. PubMed ID: 23827653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
    Jin J; Xiong Y; Cen B
    Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J; Chen Y; Wan J; Liu X; Yu C; Li W
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
    Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
    Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
    Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.
    Polier G; Giaisi M; Köhler R; Müller WW; Lutz C; Buss EC; Krammer PH; Li-Weber M
    Int J Cancer; 2015 Feb; 136(3):688-98. PubMed ID: 24895203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.
    Lopez A; Reyna DE; Gitego N; Kopp F; Zhou H; Miranda-Roman MA; Nordstrøm LU; Narayanagari SR; Chi P; Vilar E; Tsirigos A; Gavathiotis E
    Nat Commun; 2022 Mar; 13(1):1199. PubMed ID: 35256598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
    Wang C; Huang SB; Yang MC; Lin YT; Chu IH; Shen YN; Chiu YH; Hung SH; Kang L; Hong YR; Chen CH
    PLoS One; 2015; 10(3):e0120913. PubMed ID: 25811469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.